Detalles de la búsqueda
1.
MRI-guided optimisation of neoadjuvant chemotherapy duration in stage II-III HER2-positive breast cancer (TRAIN-3): a multicentre, single-arm, phase 2 study.
Lancet Oncol
; 25(5): 603-613, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38588682
2.
Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial.
Lancet Oncol
; 19(12): 1630-1640, 2018 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-30413379
3.
PD-L1 blockade in combination with carboplatin as immune induction in metastatic lobular breast cancer: the GELATO trial.
Nat Cancer
; 4(4): 535-549, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-37038006
4.
Three-Year Follow-up of Neoadjuvant Chemotherapy With or Without Anthracyclines in the Presence of Dual ERBB2 Blockade in Patients With ERBB2-Positive Breast Cancer: A Secondary Analysis of the TRAIN-2 Randomized, Phase 3 Trial.
JAMA Oncol
; 7(7): 978-984, 2021 Jul 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34014249
5.
Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial.
Nat Med
; 25(6): 920-928, 2019 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-31086347
6.
Publisher Correction: Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial.
Nat Med
; 25(7): 1175, 2019 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-31209337
7.
Toxicity of dual HER2-blockade with pertuzumab added to anthracycline versus non-anthracycline containing chemotherapy as neoadjuvant treatment in HER2-positive breast cancer: The TRAIN-2 study.
Breast
; 29: 153-9, 2016 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-27498129
Resultados
1 -
7
de 7
1
Próxima >
>>